These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34368918)

  • 1. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
    Olivieri M; Simpson M; Yan S; Fedorovsky J; Zhang X; Tomic R; Pinachyan K; Mancuso ME
    Curr Med Res Opin; 2022 Jul; 38(7):1133-1139. PubMed ID: 35387548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.
    Olivieri M; Sommerer P; Maro G; Yan S
    Eur J Haematol; 2020 Apr; 104(4):310-317. PubMed ID: 31883398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.
    Pocoski J; Li N; Ayyagari R; Church N; Maas Enriquez M; Xiang Q; Kelkar S; Du EX; Wu EQ; Xie J
    J Blood Med; 2016; 7():129-37. PubMed ID: 27445511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
    Di Brino E; Yan S; Tomic R; Panebianco M; Dlotko E; Stern L; Basile M; Rumi F; Cicchetti A; Marino R
    J Med Econ; 2023; 26(1):554-564. PubMed ID: 37039544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
    Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
    Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
    Hakimi Z; Santagostino E; Postma MJ; Nazir J
    Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.
    Raso S; Hermans C
    Expert Opin Biol Ther; 2018 Jan; 18(1):87-94. PubMed ID: 29256333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A.
    Batt K; Gao W; Ayyagari R; Deschaseaux C; Vashi PB; Yao Z; Wang Y; Kessabi S; Klamroth R
    J Blood Med; 2019; 10():147-159. PubMed ID: 31417326
    [No Abstract]   [Full Text] [Related]  

  • 12. Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians.
    Borchiellini A; Castaman G; Feola G; Ferretti A; Giordano P; Luciani M; Malcangi G; Margaglione M; Molinari AC; Pollio B; Rocino A; Santoro C; Schiavulli M; Zanon E
    J Thromb Thrombolysis; 2022 May; 53(4):934-944. PubMed ID: 34775566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lonoctocog Alfa: A Review in Haemophilia A.
    Al-Salama ZT; Scott LJ
    Drugs; 2017 Oct; 77(15):1677-1686. PubMed ID: 28900904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
    Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
    Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A.
    Graf L; Yan S; Shen MC; Balasa V
    J Med Econ; 2020 Dec; 23(12):1493-1498. PubMed ID: 32969738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis.
    Guillet B; Hassoun A; Wibaut B; Harroche A; Biron-Andréani C; Repesse Y; d'Oiron R; Tardy B; Pan Petesch B; Chamouni P; Gay V; Fouassier M; Pouplard C; Martin C; Catovic H; Delavenne X
    Thromb Haemost; 2023 May; 123(5):490-500. PubMed ID: 36758611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.